Cosmos Health Inc. (COSM)
NASDAQ: COSM · IEX Real-Time Price · USD
0.630
-0.012 (-1.95%)
At close: Apr 17, 2024, 4:00 PM
0.653
+0.023 (3.67%)
Pre-market: Apr 18, 2024, 8:00 AM EDT
Company Description
Cosmos Health Inc. provides proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, cosmetics, nursery, health care and baby products, and medical devices.
Its nutraceutical product portfolio includes Sky Premium Life and Mediterranation. The company serves wholesale pharmaceutical distributors and independent retail pharmacies.
It operates in Greece, Germany, the United Kingdom, Italy, Denmark, Croatia, and Cyprus. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Cosmos Health Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Grigorios Siokas |
Contact Details
Address: 5 Agiou Georgiou, Pilea Thessaloniki, J3 55438 Greece | |
| Phone | 312-536-3102 |
| Website | cosmosholdingsinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001474167 |
| CUSIP Number | 221413206 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Demetrios G. Demetriades | Secretary and Independent Director |
| Nikolaos Bardakis | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 424B3 | Prospectus |
| Feb 29, 2024 | 424B3 | Prospectus |
| Feb 15, 2024 | 424B3 | Prospectus |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | EFFECT | Notice of Effectiveness |
| Feb 5, 2024 | UPLOAD | Filing |
| Jan 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 22, 2024 | 8-K | Current Report |